The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth.
4-Butyrolactone
/ analogs & derivatives
Animals
Anti-Inflammatory Agents
/ administration & dosage
Biomarkers
Butylene Glycols
/ administration & dosage
Cell Line, Tumor
Cell Survival
Cytokines
/ blood
Disease Models, Animal
Dose-Response Relationship, Drug
Female
Flax
/ chemistry
Gene Expression Profiling
Glucosides
/ administration & dosage
Immunohistochemistry
Lignans
/ blood
Mammary Neoplasms, Animal
/ drug therapy
Mice
NF-kappa B
/ metabolism
Signal Transduction
/ drug effects
Breast cancer
Enterodiol (END)
Enterolactone (ENL)
NFκB
Plant lignan
Secoisolariciresinol diglucoside (SDG)
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
03
08
2018
accepted:
20
10
2018
pubmed:
28
10
2018
medline:
14
6
2019
entrez:
28
10
2018
Statut:
ppublish
Résumé
Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERα)-negative disease, and decreased preclinical mammary tumor growth. However, while preclinical studies have established that SDG and ENL affect measures of progression in models of triple-negative breast cancer (TNBC, a subset of ERα-negative disease), the molecular mechanisms underlying these effects remain unclear. C57BL/6 mice were fed a control diet (control, 10% kcal from fat) or control diet + SDG (SDG, 100 mg/kg diet) for 8 weeks, then orthotopically injected with syngeneic E0771 mammary tumor cells (a model of TNBC); tumor growth was monitored for 3 weeks. The role of reduced NF-κB signaling in SDG's anti-tumor effects was explored in vitro via treatment with the bioactive SDG metabolite ENL. In addition to the murine E0771 cells, the in vitro studies utilized MDA-MB-231 and MCF-7 cells, two human cell lines which model the triple-negative and luminal A breast cancer subtypes, respectively. SDG supplementation in the mice significantly reduced tumor volume and expression of phospho-p65 and NF-κB target genes (P < 0.05). Markers of macrophage infiltration were decreased in the distal-to-tumor mammary fat pad of mice supplemented with SDG relative to control mice (P < 0.05). In vitro, ENL treatment inhibited viability, survival, and NF-κB activity and target gene expression in E0771, MDA-MB-231, and MCF-7 cells (P < 0.05). Overexpression of Rela attenuated ENL's inhibition of E0771 cell viability and survival. SDG reduces tumor growth in the E0771 model of TNBC, likely via a mechanism involving inhibition of NF-κB activity. SDG could serve as a practical and effective adjuvant treatment to reduce recurrence, but greater understanding of its effects is needed to inform the development of more targeted recommendations for its use.
Identifiants
pubmed: 30367332
doi: 10.1007/s10549-018-5021-6
pii: 10.1007/s10549-018-5021-6
pmc: PMC6394576
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Biomarkers
0
Butylene Glycols
0
Cytokines
0
Glucosides
0
Lignans
0
NF-kappa B
0
4-Butyrolactone
OL659KIY4X
secoisolariciresinol diglucoside
T9281L29MV
2,3-bis(3'-hydroxybenzyl)butyrolactone
X01E7E1D6H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
545-557Subventions
Organisme : Susan G. Komen
ID : KG101039
Pays : United States
Organisme : Breast Cancer Research Foundation
ID : BCRF 16-075
Organisme : NCI NIH HHS
ID : R35CA197627
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK056350
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA057726
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM122741
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197627
Pays : United States
Références
Baillieres Clin Endocrinol Metab. 1998 Dec;12(4):729-42
pubmed: 10384822
Oncogene. 1999 Nov 22;18(49):6938-47
pubmed: 10602468
Nutr Cancer. 1999;35(1):50-7
pubmed: 10624706
Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8542-7
pubmed: 10900013
Mol Cancer Ther. 2002 Aug;1(10):869-76
pubmed: 12492120
Breast Cancer Res Treat. 2003 Jul;80(2):163-70
pubmed: 12908819
Toxicol Sci. 2004 Jul;80(1):14-25
pubmed: 15084758
Int J Oncol. 2004 Nov;25(5):1389-95
pubmed: 15492830
Int J Cancer. 2005 Sep 20;116(5):793-8
pubmed: 15849746
Cancer Lett. 2006 Mar 28;234(2):168-75
pubmed: 15913884
Int J Cancer. 2006 Mar 1;118(5):1316-20
pubmed: 16152607
Clin Cancer Res. 2007 Feb 1;13(3):1061-7
pubmed: 17289903
J Steroid Biochem Mol Biol. 2008 May;110(1-2):176-85
pubmed: 18457947
Cancer Lett. 2008 Oct 8;269(2):226-42
pubmed: 18492603
Carcinogenesis. 2009 Jul;30(7):1073-81
pubmed: 19468060
J Nutr. 2009 Nov;139(11):2061-6
pubmed: 19776177
Mol Nutr Food Res. 2010 Mar;54(3):415-25
pubmed: 19904759
Int J Cancer. 2010 Aug 1;127(3):737-45
pubmed: 19924815
Am J Clin Nutr. 2010 Jul;92(1):141-53
pubmed: 20463043
Cancer Prev Res (Phila). 2010 Oct;3(10):1342-50
pubmed: 20724470
Cancer Res. 2011 Jan 1;71(1):51-60
pubmed: 21097717
Breast Cancer Res Treat. 2011 Aug;128(3):883-9
pubmed: 21340481
Cancer Biol Ther. 2011 May 15;11(10):910-7
pubmed: 21451264
Int J Cancer. 2012 Mar 15;130(6):1401-10
pubmed: 21544804
Ann N Y Acad Sci. 2011 Jul;1229:45-52
pubmed: 21793838
J Clin Oncol. 2011 Oct 1;29(28):3730-8
pubmed: 21900115
Br J Cancer. 2011 Oct 11;105(8):1151-7
pubmed: 21915130
Anticancer Res. 2011 Oct;31(10):3301-13
pubmed: 21965740
Carcinogenesis. 2012 Jan;33(1):203-8
pubmed: 22080573
Breast Cancer Res Treat. 2012 Apr;132(2):661-8
pubmed: 22094938
Cancer Prev Res (Phila). 2012 Jul;5(7):930-42
pubmed: 22588949
Indian J Cancer. 2012 Jan-Mar;49(1):181-7
pubmed: 22842186
Breast Cancer Res. 2013;15(4):R59
pubmed: 23880059
Food Funct. 2014 Mar;5(3):491-501
pubmed: 24429845
Int J Cancer. 2014 Aug 15;135(4):923-33
pubmed: 24436155
Dis Model Mech. 2015 Mar;8(3):237-51
pubmed: 25633981
Nutr Cancer. 2015;67(5):857-64
pubmed: 26010915
Nutr Cancer. 2015;67(8):1324-32
pubmed: 26473769
Cells. 2016 Mar 18;5(1):null
pubmed: 26999213
Toxicol Appl Pharmacol. 2016 Dec 15;313:180-194
pubmed: 27984132
Mol Nutr Food Res. 2017 Sep;61(9):
pubmed: 28370954
Cancer Res. 2017 May 1;77(9):2500-2511
pubmed: 28373182
Oncotarget. 2017 May 9;8(19):30621-30643
pubmed: 28430642
Asian Pac J Cancer Prev. ;18(4):905-915
pubmed: 28545187
Nutr Cancer. 2018 Feb-Mar;70(2):306-315
pubmed: 29303360
Mol Cancer Res. 2018 May;16(5):869-879
pubmed: 29453319
J Appl Bacteriol. 1985 Jan;58(1):37-43
pubmed: 2984153
Int J Cancer. 2018 Dec 1;143(11):2698-2708
pubmed: 29974464
Nutr Cancer. 1996;26(2):159-65
pubmed: 8875553
Mol Cell Biol. 1997 Jul;17(7):3629-39
pubmed: 9199297
J Clin Invest. 1997 Dec 15;100(12):2952-60
pubmed: 9399940
Br J Nutr. 1998 Jan;79(1):37-45
pubmed: 9505801